{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:federal-register-2024-20062:v1","objectPathId":"federal-register-2024-20062-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/federal-register-2024-20062/","json":"https://peptidescanner.com/evidence/v1/objects/federal-register-2024-20062-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/federal-register-2024-20062-v1.md"},"story":{"slug":"federal-register-2024-20062","version":1,"domain":"Regulatory","dateInSource":"2024-09-06","sourceCheckedAt":"2026-08-21","publishedAt":"2026-08-21","peptideSlugs":["elamipretide"],"peptides":[{"slug":"elamipretide","url":"https://peptidescanner.com/peptides/elamipretide/"}]},"claims":[{"id":"headline","text":"Federal Register notice 2024-20062","sourceIds":["federal-register-2024-20062-66035b025ae4"]},{"id":"summary","text":"The Federal Register published notice 2024-20062, attributed to FDA and its parent HHS department, on 2024-09-06. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 215244 for Elamipretide Hydrochloride Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide.","sourceIds":["federal-register-2024-20062-66035b025ae4"]},{"id":"paragraph-1","text":"The Federal Register published notice 2024-20062, attributed to FDA and its parent HHS department, on 2024-09-06. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 215244 for Elamipretide Hydrochloride Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide.","sourceIds":["federal-register-2024-20062-66035b025ae4"]},{"id":"paragraph-2","text":"This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use.","sourceIds":["federal-register-2024-20062-66035b025ae4"]}],"sources":[{"id":"federal-register-2024-20062-66035b025ae4","name":"Federal Register via GovInfo","sourceClass":"A","title":"Federal Register notice 2024-20062 · published 2024-09-06 · Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 215244 for Elamipretide Hydrochloride Injection","url":"https://www.govinfo.gov/content/pkg/FR-2024-09-06/pdf/2024-20062.pdf"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"d7c54907dd29979b7abb3d8c8d749eddb6590e65fc35ba30802ba694e16630e6","tierARecordSha256":"66035b025ae48de87f69e1912652e243013896849051921a44a5b554ebd540c6"},"integrity":{"algorithm":"sha256","contentSha256":"b697996b9c2d2b57d9c08c2a35db5ee3f310191a631e7b2d388f9510af202aaa"}}